Cannabidiol (Epidiolex) vs Cannabidiol (Kanbis)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Dravet Syndrome
Shared mechanism: cannabinoid · full Dravet Syndrome pipeline
Cannabidiol (Epidiolex)
Marketed by Jazz Pharmaceuticals and partners
NCT02091375 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial of 120 participants (61 receiving cannabidiol and 59 placebo) using convulsive seizure frequency as its primary clinical endpoint. The primary comparison was met: median seizure frequency fell 38.94% with cannabidiol versus 13.29% with placebo, with p=0.0123.
Next expected readout: August 2027 · NCT05044819 (registry estimate)
Reported efficacy
Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2) (met)
Result source: NCT02091375
Cannabidiol (Kanbis)
Marketed by Laboratorio Elea Phoenix S.A.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Dravet Syndrome
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Cannabidiol (Kanbis): no structured comparison results are available for Dravet Syndrome.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Cannabidiol (Epidiolex)
show 2 more results
show 4 more results
Available safety results
Cannabidiol (Epidiolex)
| Dropout rate | 14.8%20 mg/kg/day NCT02091375 · Phase 3 show 7 more results46%Dravet Syndrome NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy 33.6%Lennox-Gastaut Syndrome NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy 9%20 mg/kg/Day NCT02224703 · Phase 3 · registry result, not featured evidence 4.5%10 mg/kg/Day NCT02224703 · Phase 3 · registry result, not featured evidence 11.1%20 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence 12.5%10 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence 0%5 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | 13.1%20 mg/kg/day NCT02091375 · Phase 3 show 7 more results8.3%Dravet Syndrome NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy 10.4%Lennox-Gastaut Syndrome NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy 7.5%20 mg/kg/Day NCT02224703 · Phase 3 · registry result, not featured evidence 0%10 mg/kg/Day NCT02224703 · Phase 3 · registry result, not featured evidence 0%20 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence 12.5%10 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence 0%5 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 16.4%20 mg/kg/day NCT02091375 · Phase 3 show 7 more results42.2%Dravet Syndrome NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy 42.9%Lennox-Gastaut Syndrome NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy 24.6%20 mg/kg/Day NCT02224703 · Phase 3 · registry result, not featured evidence 20.3%10 mg/kg/Day NCT02224703 · Phase 3 · registry result, not featured evidence 11.1%20 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence 25%10 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence 10%5 mg/kg/day NCT02091206 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 20 mg/kg/day diarrhoea 31.1% (placebo 10.2%) somnolence 31.1% (placebo 10.2%) decreased appetite 26.2% (placebo 5.1%) NCT02091375 · Phase 3 show 7 more resultsdiarrhoea 42.2% pyrexia 37.1% decreased appetite 31.4% NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy diarrhoea 37.7% pyrexia 33.6% convulsion 32.8% NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy 20 mg/kg/Day decreased appetite 27.5% (placebo 16.9%) diarrhoea 26.1% (placebo 12.3%) somnolence 23.2% (placebo 13.8%) NCT02224703 · Phase 3 · registry result, not featured evidence 10 mg/kg/Day pyrexia 23.4% (placebo 16.9%) somnolence 21.9% (placebo 13.8%) diarrhoea 17.2% (placebo 12.3%) NCT02224703 · Phase 3 · registry result, not featured evidence 20 mg/kg/day decreased appetite 44.4% (placebo 0%) abdominal pain upper 22.2% (placebo 0%) sedation 22.2% (placebo 0%) NCT02091206 · Phase 2 · registry result, not featured evidence 10 mg/kg/day somnolence 37.5% (placebo 14.3%) coordination abnormal 12.5% (placebo 0%) decreased appetite 12.5% (placebo 0%) NCT02091206 · Phase 2 · registry result, not featured evidence 5 mg/kg/day abnormal behaviour 30% (placebo 0%) pyrexia 30% (placebo 0%) ataxia 20% (placebo 0%) NCT02091206 · Phase 2 · registry result, not featured evidence |
Lennox-Gastaut Syndrome
Shared mechanism: cannabinoid · full Lennox-Gastaut Syndrome pipeline
Cannabidiol (Epidiolex)
Marketed by Jazz Pharmaceuticals and partners
NCT02224690 · Phase 3 · completed
Participants were randomized to cannabidiol (86) or matching placebo (85), with participants, caregivers, investigators, and outcome assessors blinded. The primary seizure-frequency endpoint was statistically met in favor of cannabidiol (p=0.0135), but no primary-endpoint power calculation is reported in the available sources, so the evidence is graded as moderate rather than strong.
Next expected readout: August 2027 · NCT05044819 (registry estimate)
Reported efficacy
Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -41.86 percentage change (IQR -72.4 to -1.3) | GWP42003-P 10 mg/kg/Day Dose -37.16 percentage change (IQR -63.8 to -5.6) vs Placebo -17.17 percentage change (IQR -37.1 to 0.9) (met)
Result source: NCT02224560
Cannabidiol (Kanbis)
Marketed by Laboratorio Elea Phoenix S.A.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Lennox-Gastaut Syndrome
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Cannabidiol (Kanbis): no structured comparison results are available for Lennox-Gastaut Syndrome.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Cannabidiol (Epidiolex)
show 2 more results
show 2 more results
show 2 more results
show 3 more results
Available safety results
Cannabidiol (Epidiolex)
| Dropout rate | 16.3%20 mg/kg/day NCT02224690 · Phase 3 show 4 more results11.8%20 mg/kg/day NCT02224560 · Phase 3 2.7%10 mg/kg/day NCT02224560 · Phase 3 46%Dravet Syndrome NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy 33.6%Lennox-Gastaut Syndrome NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy |
|---|---|
| Discontinued due to AEs | 9.3%20 mg/kg/day NCT02224690 · Phase 3 show 4 more results5.3%20 mg/kg/day NCT02224560 · Phase 3 1.4%10 mg/kg/day NCT02224560 · Phase 3 8.3%Dravet Syndrome NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy 10.4%Lennox-Gastaut Syndrome NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy |
| Serious AEs | 23.3%20 mg/kg/day NCT02224690 · Phase 3 show 4 more results—20 mg/kg/day NCT02224560 · Phase 3 —10 mg/kg/day NCT02224560 · Phase 3 42.2%Dravet Syndrome NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy 42.9%Lennox-Gastaut Syndrome NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy |
| Most frequent reported AEs | 20 mg/kg/day diarrhoea 18.6% (placebo 8.2%) somnolence 14% (placebo 9.4%) decreased appetite 12.8% (placebo 2.4%) NCT02224690 · Phase 3 show 2 more resultsdiarrhoea 42.2% pyrexia 37.1% decreased appetite 31.4% NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy diarrhoea 37.7% pyrexia 33.6% convulsion 32.8% NCT02224573 · Phase 3 · registry result, not featured evidence · monotherapy |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cannabidiol (Epidiolex)'s landscape · Cannabidiol (Kanbis)'s landscape